Top 230+ Biotech Companies In Bay Area In 2021
← Visit blog

Top 230+ Biotech Companies In Bay Area In 2021

Updated on March 10th, 2021

Top 230+ Biotech Companies In Bay Area In 2021

A hand curated list of 230+ top biotech companies in Bay Area.
Whether you run a digital agency, a B2B company, or just want to connect with fast growing companies, this is the list for you.
In our premium lists, we also include: • 20+ data points for each company
• Services they’re likely to outsource
• CEO Information & Email
If you’re interested in our premium lists, consider subscribing to our monthly report of tech companies.


Table Of Contents

  1. AcelRx Pharmaceuticals (Less than $1M)
  2. Microvi Biotechnologies (Less than $1M)
  3. Vineti ($1M to $10M)
  4. Nano Precision Medical ($1M to $10M)
  5. Perfect Day ($1M to $10M)
  6. Tranquis Therapeutics ($1M to $10M)
  7. Endogena Therapeutics (Less than $1M)
  8. Biome Makers ($1M to $10M)
  9. Semiotic AI (Less than $1M)
  10. Trident Bioscience (Less than $1M)
  11. Gritstone Oncology (Less than $1M)
  12. Intabio (Less than $1M)
  13. Synthekine ($10M to $50M)
  14. Xalud Therapeutics (Less than $1M)
  15. Novome Biotechnologies ($1M to $10M)
  16. BioMarin Pharmaceutical ($100M to $500M)
  17. Sonoma BioTherapeutics ($1M to $10M)
  18. Senti Biosciences (Less than $1M)
  19. Insitro ($1M to $10M)
  20. Mission Bio ($10M to $50M)
  21. Cage Bio ($1M to $10M)
  22. Axent Biosciences (Less than $1M)
  23. Genome Medical ($1M to $10M)
  24. Astalake Biosystems (Less than $1M)
  25. PACT Pharma ($10M to $50M)
  26. Federation Bio (Less than $1M)
  27. NGM Biopharmaceuticals ($10M to $50M)
  28. Earli (Less than $1M)
  29. TrueBinding ($10M to $50M)
  30. NeuroPace ($10M to $50M)
  31. Andes ($1M to $10M)
  32. Octave Bioscience (Less than $1M)
  33. Kronos Bio ($1M to $10M)
  34. Brightseed ($10M to $50M)
  35. Newomics ($10M to $50M)
  36. Evommune ($10M to $50M)
  37. Aligos Therapeutics ($1M to $10M)
  38. CellFE (Less than $1M)
  39. Synthego ($10M to $50M)
  40. AFINGEN® ($1M to $10M)
  41. Assertio Therapeutics ($100M to $500M)
  42. General Automation Lab Technologies (Less than $1M)
  43. MycoWorks ($1M to $10M)
  44. Olema Oncology ($1M to $10M)
  45. Siolta Therapeutics (Less than $1M)
  46. CH4 Global (Less than $1M)
  47. LiVeritas Biosciences ($10M to $50M)
  48. CytomX Therapeutics ($10M to $50M)
  49. Vir Biotechnology ($1M to $10M)
  50. Clear Labs ($1M to $10M)
  51. Benchling ($1M to $10M)
  52. Pheronym (Less than $1M)
  53. Vaxcyte ($1M to $10M)
  54. Nutcracker Therapeutics (Less than $1M)
  55. Immune-Onc Therapeutics ($1M to $10M)
  56. Aimmune Therapeutics ($10M to $50M)
  57. Altay Therapeutics (Less than $1M)
  58. Biomea Fusion ($10M to $50M)
  59. Sutro Biopharma ($10M to $50M)
  60. D2G Oncology (Less than $1M)
  61. Cytek Biosciences ($1M to $10M)
  62. Change Foods ($10M to $50M)
  63. Datavant ($1M to $10M)
  64. CODA Biotherapeutics ($1M to $10M)
  65. Revolution Medicines ($10M to $50M)
  66. Menten AI (Less than $1M)
  67. Veracyte ($10M to $50M)
  68. PicnicHealth ($1M to $10M)
  69. Virus Geeks Inc. (Less than $1M)
  70. Corvus Pharmaceuticals ($1M to $10M)
  71. Darmiyan ($10M to $50M)
  72. Spectrum Antimicrobials ($10M to $50M)
  73. Zymergen ($100M to $500M)
  74. Trace Genomics ($1M to $10M)
  75. Pionyr Immunotherapeutics (Less than $1M)
  76. Assertio ($50M to $100M)
  77. Rakuten Medical ($10M to $50M)
  78. SonALAsense ($10M to $50M)
  79. Day One Biopharmaceuticals ($10M to $50M)
  80. Geltor ($1M to $10M)
  81. Ashvattha Therapeutics (Less than $1M)
  82. Perfuse Therapeutics ($10M to $50M)
  83. CareDx ($10M to $50M)
  84. Alladapt Immunotherapeutics ($1M to $10M)
  85. Lyell Immunopharma ($10M to $50M)
  86. Tolerion ($1M to $10M)
  87. SilviaTerra ($1M to $10M)
  88. Enable Medicine ($10M to $50M)
  89. Amunix ($1M to $10M)
  90. LevitasBio ($1M to $10M)
  91. Mantra Bio ($1M to $10M)
  92. Pacific Biosciences ($10M to $50M)
  93. Alamar Biosciences ($1M to $10M)
  94. ZBiotics (Less than $1M)
  95. NuLeaf Tech Inc (Less than $1M)
  96. OncoCyte (Less than $1M)
  97. Genetic Foresight ($1M to $10M)
  98. Air Protein ($10M to $50M)
  99. Hospi (Less than $1M)
  100. ApexQubit ($1M to $10M)
  101. Natera ($50M to $100M)
  102. Genapsys ($1M to $10M)
  103. Ivy Natal ($10M to $50M)
  104. Frontier Bio (Less than $1M)
  105. Nurix Therapeutics ($10M to $50M)
  106. Ace Vision Group ($10M to $50M)
  107. LeafWorks ($1M to $10M)
  108. Koya Medical ($10M to $50M)
  109. BillionToOne ($1M to $10M)
  110. Nautilus Biotechnology ($10M to $50M)
  111. InterVenn (Less than $1M)
  112. Kenzen (Less than $1M)
  113. Bolt Biotherapeutics (Less than $1M)
  114. Facile Therapeutics ($10M to $50M)
  115. Nesos ($10M to $50M)
  116. Brex ($10M to $50M)
  117. Protera ($1M to $10M)
  118. Retrotope (Less than $1M)
  119. Corinth MedTech ($1M to $10M)
  120. Eureka Therapeutics ($10M to $50M)
  121. EnGen Bio ($10M to $50M)
  122. Felix Biotechnology (Less than $1M)
  123. Tulavi Therapeutics ($1M to $10M)
  124. Freenome ($10M to $50M)
  125. Arcus Biosciences ($1M to $10M)
  126. Dropprint Genomics ($10M to $50M)
  127. Rigel Pharmaceuticals ($10M to $50M)
  128. Rubedo Life Sciences ($10M to $50M)
  129. 23andMe ($100M to $500M)
  130. Apollomics ($1M to $10M)
  131. PMV Pharmaceuticals ($10M to $50M)
  132. New Age Meats (Less than $1M)
  133. Coral Genomics (Less than $1M)
  134. Inflammatix ($1M to $10M)
  135. Dren Bio ($10M to $50M)
  136. Sagimet Biosciences ($1M to $10M)
  137. Apexigen ($1M to $10M)
  138. Pivot Bio ($1M to $10M)
  139. rBIO (Less than $1M)
  140. Oyster Point Pharmaceuticals ($100M to $500M)
  141. Revelation Biosciences ($10M to $50M)
  142. protocols.io ($1M to $10M)
  143. Carmot Therapeutics (Less than $1M)
  144. Celevity ($1M to $10M)
  145. SOMOS (Less than $1M)
  146. Tallac Therapeutics ($10M to $50M)
  147. Pliant Therapeutics ($10M to $50M)
  148. CytoVale (Less than $1M)
  149. Seer (Less than $1M)
  150. Ionpath ($1M to $10M)
  151. BigHat Biosciences (Less than $1M)
  152. AmbAgon Therapeutics ($10M to $50M)
  153. VastBiome ($1M to $10M)
  154. Soley Therapeutics (Less than $1M)
  155. Titan Pharmaceuticals (Less than $1M)
  156. Genesis Therapeutics ($1M to $10M)
  157. Biotricity (Less than $1M)
  158. Durect Corp. ($10M to $50M)
  159. BioXplor (Less than $1M)
  160. Vivace Therapeutics ($1M to $10M)
  161. ANA Therapeutics (Less than $1M)
  162. DiCE Molecules (Less than $1M)
  163. IgGenix (Less than $1M)
  164. Q Bio ($1M to $10M)
  165. Encoded Therapeutics (Less than $1M)
  166. Catalyst Biosciences (Less than $1M)
  167. Amyris ($10M to $50M)
  168. Imago BioSciences ($10M to $50M)
  169. IDbyDNA ($1M to $10M)
  170. Cellares ($10M to $50M)
  171. Kyverna Therapeutics (Less than $1M)
  172. Fountain Therapeutics ($1M to $10M)
  173. Deepcell (Less than $1M)
  174. Surrozen ($1M to $10M)
  175. MicroByre (Less than $1M)
  176. Equator Therapeutics ($1M to $10M)
  177. Amfora ($10M to $50M)
  178. Vera Therapeutics ($1M to $10M)
  179. PETcoil (Less than $1M)
  180. Tiamat Sciences (Less than $1M)
  181. Terns Pharmaceuticals ($10M to $50M)
  182. Mekonos Inc. ($1M to $10M)
  183. Swiftscale Biologics (Less than $1M)
  184. Kodiak Sciences ($1M to $10M)
  185. Annexon Biosciences ($1M to $10M)
  186. Onc.AI (Less than $1M)
  187. Karius ($10M to $50M)
  188. MicuRx Pharmaceuticals ($10M to $50M)
  189. Qualio ($10M to $50M)
  190. Rani Therapeutics ($1M to $10M)
  191. Aerin Medical ($1M to $10M)
  192. Cyagen Biosciences ($1M to $10M)
  193. 89bio ($1M to $10M)
  194. Artemys Foods ($10M to $50M)
  195. ProLynx ($10M to $50M)
  196. Pylum Biosciences ($10M to $50M)
  197. Actym ($1M to $10M)
  198. Spruce Biosciences ($1M to $10M)
  199. Cellworks (Less than $1M)
  200. Circle Pharma ($1M to $10M)
  201. Attralus ($10M to $50M)
  202. AHEAD Medicine (Less than $1M)
  203. Sound Agriculture ($10M to $50M)
  204. Spotlight Therapeutics (Less than $1M)
  205. Color ($50M to $100M)
  206. Invenio Imaging ($1M to $10M)
  207. Boost Biomes ($1M to $10M)
  208. Kriya Therapeutics ($1M to $10M)
  209. Personalis ($10M to $50M)
  210. ImmunoMind ($10M to $50M)
  211. Helix ($10M to $50M)
  212. Tizona Therapeutics ($1M to $10M)
  213. Base5 Genomics ($10M to $50M)
  214. DNAnexus ($10M to $50M)
  215. PostEra ($1M to $10M)
  216. Codiak Biosciences ($10M to $50M)
  217. Hexagon Bio ($10M to $50M)
  218. Orbus Therapeutics (Less than $1M)
  219. Checkerspot (Less than $1M)
  220. BrightInsight ($1M to $10M)
  221. Culture Biosciences ($1M to $10M)
  222. InCarda Therapeutics ($1M to $10M)
  223. Enveda Biosciences ($10M to $50M)
  224. Rain Therapeutics ($1M to $10M)
  225. Grail ($50M to $100M)
  226. Unlearn.AI ($1M to $10M)
  227. Ansa Biotechnologies ($10M to $50M)
  228. Uniphore ($1M to $10M)
  229. 4D Molecular Therapeutics ($10M to $50M)
  230. Katana Pharmaceuticals ($10M to $50M)
  231. Ceribell ($10M to $50M)
  232. Correlia Biosystems ($1M to $10M)
  233. BIOAGE LABS (Less than $1M)
  234. Coherus Biosciences ($100M to $500M)
  235. Syapse ($1M to $10M)


  1. AcelRx Pharmaceuticals (Less than $1M)

    AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of pain and other conditions. It offers NanoTab, a tablet for oral transmucosal administration. The company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute post-operative pain in the hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures. It serves patients, physicians, regulators, and payers. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is based in Redwood City, California.

    • Less than $1M annual revenues
    • 51-100 employees
    • $27.5M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  2. people sitting on black chairs


  3. Microvi Biotechnologies (Less than $1M)

    Microvi is a biotechnology company that discovers, develops, manufactures, and commercializes innovative biocatalytic solutions in the water, energy, and chemical industries. The company’s core discipline is its MicroNiche Engineering platform technology, where the microenvironment of biological systems is precisely designed to enhance microbial life and optimize metabolic performance. Microvi’s MicroNiche Engineering enables cost-effective economics, a smaller footprint and increased productivity compared to current methods. It seeks to develop key partnerships and alliances with industry leaders that will leverage the cutting-edge solutions that Microvi has developed.

    • Less than $1M annual revenues
    • 11-50 employees
    • $1.1M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  4. people sitting on chairs near tables during daytime


  5. Vineti ($1M to $10M)

    Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $33M raised in October, 2020
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  6. rectangular brown wooden table


  7. Nano Precision Medical ($1M to $10M)

    Nano Precision Medical develops small subdermal implants with the NanoPortal membrane to provide long-term therapeutics for the treatment of chronic diseases. Nano Precision Medical is a pre-clinical stage company, founded in 2009 and based in Emeryville, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $13M raised in October, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  8. Perfect Day ($1M to $10M)

    Perfect Day produces dairy proteins that are nutritionally identical to proteins from cow’s milk. Perfect Day is pioneering a whole new era in animal-free dairy products. One the delivers all of the taste, texture, and nutrition of dairy with none of the food safety, environmental, or animal welfare downsides. The company's animal-free approach, based on the safe and proven techniques that give the consumers beer or vegetarian rennet also provides consumers and food manufacturers with the same product they all know and love - through a more sustainable and compassionate process. It was founded in 2014 and is headquartered in Emeryville, California.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $160M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  9. brown wooden table and chairs


  10. Tranquis Therapeutics ($1M to $10M)

    Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company’s portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $30M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  11. selective focus photography of desk lamp on table


  12. Endogena Therapeutics (Less than $1M)

    Endogena Therapeutics is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena's approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders. The company implements innovation in the field of regenerative medicine. Their science combines the latest developments in stem cell biology, AI, and expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases.

    • Less than $1M annual revenues
    • 1-10 employees
    • $8M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  13. rolling armchair beside table


  14. Biome Makers ($1M to $10M)

    Biome Makers is a biotech company born in Silicon Valley specialized in the identification and understanding of the microbiome. They use DNA Sequencing technologies and proprietary Intelligent Computing systems to ease detailed information and recommendations that allow customers improve their agricultural production and the quality of their products.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $2M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  15. three women sitting around table using laptops


  16. Semiotic AI (Less than $1M)

    Semiotic AI provides encrypted computing services in the cloud based on Fully Homomorphic Encryption (FHE). Using Semiotic's services, organizations can offer data analytics on sensitive data without compromising security and privacy. In addition to data security, Semiotic's technology can protect proprietary models by encrypting them before deployment. Privacy and security will play a pivotal role in business growth in the era of cloud computing, AI, and 5G. Semiotic's founders bring decades of experience in cryptography, AI, and acceleration to prepare you for this future. It was founded in 2020 and is headquartered in Los Altos, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in May, 2020
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  17. grayscale photo of people in room


  18. Trident Bioscience (Less than $1M)

    Trident Bioscience is a biotech company that stays abreast of the latest technological trends in leading protein structure.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in August, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  19. men sitting of chair inside room


  20. Gritstone Oncology (Less than $1M)

    Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. Gritstone Oncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS.

    • Less than $1M annual revenues
    • 101-250 employees
    • $125M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  21. Intabio (Less than $1M)

    Intabio, Inc. is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing.

    • Less than $1M annual revenues
    • 11-50 employees
    • $18M raised in February, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  22. people sitting in front of computer monitors


  23. Synthekine ($10M to $50M)

    Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $82M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  24. man in gray sweatshirt sitting on chair in front of iMac


  25. Xalud Therapeutics (Less than $1M)

    Xalud Therapeutics is a biotech company that develops therapies for the treatment of neuro-inflammatory diseases. It offers a gene therapy platform that addresses chronic pain. The lead product candidate, XT-150 is in two P2 clinical studies for the treatment of Osteoarthritis Pain. Xalud is a portfolio company of PBM Capital Group. The company was established in 2009 and is based in San Francisco, California, United States.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  26. people using desktop computer inside office


  27. Novome Biotechnologies ($1M to $10M)

    Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $33M raised in January, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  28. group of people sitting beside rectangular wooden table with laptops


  29. BioMarin Pharmaceutical ($100M to $500M)

    BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

    • $100M to $500M annual revenues
    • 1001-5000 employees
    • $585.8M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  30. rectangular brown wooden table with chair lot inside building


  31. Sonoma BioTherapeutics ($1M to $10M)

    Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $30M raised in September, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  32. grey wooden table and black leather rolling chairs


  33. Senti Biosciences (Less than $1M)

    Senti Biosciences is a developer of a programmable biology platform for cancer therapies. Its therapeutics specialize in cell engineering and biological programming to build the future of gene and cell-based therapies that enable physicians to give patients life-saving treatments at an affordable cost.

    • Less than $1M annual revenues
    • 51-100 employees
    • $105M raised in January, 2021
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  34. people having meeting on rectangular brown table


  35. Insitro ($1M to $10M)

    Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $143M raised in May, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  36. man and woman sitting at table


  37. Mission Bio ($10M to $50M)

    Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $70M raised in August, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  38. brown and white table and chairs


  39. Cage Bio ($1M to $10M)

    Cage Bio is a privately-held clinical-stage company exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology. The company's mission is to develop highly effective topical products for localized treatment thereby minimizing side effects from systemic exposure. Cage Bio is headquartered in San Carlos, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $7.2M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  40. two women sitting beside table using MacBooks


  41. Axent Biosciences (Less than $1M)

    Axent Biosciences is a biotech venture that engineers biomaterial technology for the development pipeline of stem cell therapy. The company was co-founded by Riya Muckom and David Schaffer in 2019 and is headquartered in Oakland, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.1M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  42. tennis table in room


  43. Genome Medical ($1M to $10M)

    Genome Medical is a national telegenomics technology, services, and strategy company bringing genomic medicine to everyday care. Through its nationwide network of genetic specialists and an efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. They also help health care providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care. The company was founded in 2016 and is based in South San Francisco, California, United States.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $0.3M raised in July, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  44. photo of industrial machines near table


  45. Astalake Biosystems (Less than $1M)

    Astalake Biosystems develops a low-cost large-scale high-yielding botanical-based biomanufacturing system of high-value natural-chemicals, nutraceuticals, and translational medicines.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in July, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  46. people standiunmg


  47. PACT Pharma ($10M to $50M)

    Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.The company's therapies help in the identification of neo-epitopes that serve as private mutations for each patient's cancer as well as creates an opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $75M raised in January, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  48. people sitting beside rectangular brown table with laptops


  49. Federation Bio (Less than $1M)

    Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role. The company's microbial therapy leverages naturally occurring or engineered bacteria along with a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses. This approach has potential in a wide range of human conditions, from metabolic disorders and cholestatic diseases to cancer and autoimmune conditions.

    • Less than $1M annual revenues
    • 11-50 employees
    • $50M raised in October, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  50. men using computers


  51. NGM Biopharmaceuticals ($10M to $50M)

    NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $125M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  52. two men using computers


  53. Earli (Less than $1M)

    Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics.

    • Less than $1M annual revenues
    • 11-50 employees
    • $40M raised in January, 2021
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  54. architectural photo of buildings during daytime


  55. TrueBinding ($10M to $50M)

    TrueBinding is an early-stage biotherapeutics development company focused on creating new and exciting molecules for applications in Immuno oncology and other disease areas with a great unmet medical needs. Based on the application of the TruebindingTM platform, TrueBinding has to date discovered 6 novel ligands, previously uncharacterized, to receptors of known checkpoint inhibitor pathways.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $49.7M raised in July, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  56. man in black jacket sitting on chair


  57. NeuroPace ($10M to $50M)

    NeuroPace designs develops, manufactures, and markets implantable devices for the treatment of neurological disorders. It offers a responsive Neurostimulator system (RNS) for the treatment of medically refractory partial epilepsy. The company's RNS system consists of implantable components, including RNS neurostimulator that delivers a short train of electrical pulses to the brain, and depth leads and cortical strip leads; and external products, such as the programmer, a laptop computer with proprietary software that has a wand and telemetry interface enabling communication with an implanted RNS neurostimulator. NeuroPace was incorporated in 1997 and is based in Mountain View, California.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $34M raised in August, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  58. people sitting and using laptops


  59. Andes ($1M to $10M)

    Andes is an agriculture and farming company based in Emeryville, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $5M raised in October, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  60. people sitting on black chairs


  61. Octave Bioscience (Less than $1M)

    Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.

    • Less than $1M annual revenues
    • 11-50 employees
    • $32M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  62. people sitting on chairs near tables during daytime


  63. Kronos Bio ($1M to $10M)

    Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $155M raised in August, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  64. rectangular brown wooden table


  65. Brightseed ($10M to $50M)

    Brightseed is a biotechnology company that features artificial intelligence that reveals powerful compounds hidden in nature. The company enables a healthier future by illuminating and activating the connections between people and plants. It was founded in 2017 and headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $27M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  66. Newomics ($10M to $50M)

    Newomics is an early stage biotechnology company that commercializes innovative and integrative platforms and solutions for personalized healthcare. Its proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS) and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $7.9M raised in December, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  67. brown wooden table and chairs


  68. Evommune ($10M to $50M)

    Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines for inflammatory diseases.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $12.5M raised in November, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  69. selective focus photography of desk lamp on table


  70. Aligos Therapeutics ($1M to $10M)

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $125M raised in January, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  71. rolling armchair beside table


  72. CellFE (Less than $1M)

    CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.

    • Less than $1M annual revenues
    • 1-10 employees
    • $4.8M raised in January, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  73. three women sitting around table using laptops


  74. Synthego ($10M to $50M)

    Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. The company was founded in 2012 and is based in Redwood City, California.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $100M raised in August, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  75. grayscale photo of people in room


  76. AFINGEN® ($1M to $10M)

    As the world's population reaches 9.7 billion in the year 2050, global crop production will need to double to meet the projected demands for food, feed, fiber, and fuel. AFINGEN® develops novel biotechnology platforms for crops to grow faster and healthier and meet the natural resource demand in new sustainable manners.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.1M raised in July, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  77. men sitting of chair inside room


  78. Assertio Therapeutics ($100M to $500M)

    Assertio Therapeutics is a biotechnology company based in Newark, California.

    • $100M to $500M annual revenues
    • 251-500 employees
    • $42.5M raised in March, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  79. General Automation Lab Technologies (Less than $1M)

    GALT is a developer of a microbiological technology used to help cultivate and study bacteria and other microbes. Its platform develops novel technologies that vastly increase the ability to study microbes, the single most diverse and impact group of organisms on the planet that enable scientists to uncover deeper insights into microbiome-based applications in agriculture, human health, environment, and industry. The company's mission is to transform microbiome science through high-throughput microbial isolation and cultivation array system. General Automation Lab Technologies was established in 2014 and is headquartered in San Carlos, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $15M raised in December, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  80. people sitting in front of computer monitors


  81. MycoWorks ($1M to $10M)

    MycoWorks is engaged in the creation of sustainable design solutions with advanced biomaterials. The company’s proprietary custom-engineered material is sustainable, versatile, and animal-free, and feels and performs like leather. Their first product, Reishi, and the proprietary platform to make it, Fine Mycelium, are a groundbreaking approach to biomaterials that delivers unparalleled versatility and unmatched performance in strength, durability, and hand feel. The perfect intersection of art and science, Reishi is the only natural material that performs like cowhide leather and is engineered to meet the highest quality standards. MycoWorks was founded by Sophia Wang and Philip Ross in 2013 and is based in San Francisco, California.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $45M raised in November, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  82. man in gray sweatshirt sitting on chair in front of iMac


  83. Olema Oncology ($1M to $10M)

    Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development. Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $85M raised in October, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  84. people using desktop computer inside office


  85. Siolta Therapeutics (Less than $1M)

    Siolta Therapeutics is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company leverages its deep knowledge of the developing gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases, enabling medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics to prevent inflammatory processes.

    • Less than $1M annual revenues
    • 1-10 employees
    • $30M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  86. group of people sitting beside rectangular wooden table with laptops


  87. CH4 Global (Less than $1M)

    CH4 Global is an aquaculture solutions provider dedicated to urgently impacting climate change. Lead by a world-class team of senior business builders, scientists and entrepreneurs, the company is initially leveraging proven science and technology for growing seaweed into innovative new livestock supplement that reduces methane produced by cows by up to 90%. Among early investors are a select group of prominent family offices and private investors. CH4 Global have also received non-dilutive capital support from government organizations from around the world. CH4 Global is a Delaware corporation based in San Francisco, CA.

    • Less than $1M annual revenues
    • 1-10 employees
    • $3M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  88. rectangular brown wooden table with chair lot inside building


  89. LiVeritas Biosciences ($10M to $50M)

    LiVeritas Biosciences is a hybrid life science data and analytics company solving the problem of mass spectrometry implementation in the world of drug development. We utilize transformative solutions that unify drug development knowledge, data, insights, and strategy. As a result, we are empowering our clients to harness the power of molecular integrity for early informed decision-making helping them advance the right candidates early in drug development.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in May, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  90. grey wooden table and black leather rolling chairs


  91. CytomX Therapeutics ($10M to $50M)

    CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $93.6M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  92. people having meeting on rectangular brown table


  93. Vir Biotechnology ($1M to $10M)

    Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $250M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  94. man and woman sitting at table


  95. Clear Labs ($1M to $10M)

    Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating the only fully-automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $18M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  96. brown and white table and chairs


  97. Benchling ($1M to $10M)

    Benchling is the modern software platform purpose-built for life science R&D. Hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering depend on our suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions. Benchling is powering breakthrough research on biotherapeutics, biofuels, and biomaterials at leading life science companies and the world's most renowned academic labs. The company is focusing on life science collaboration, both private and public, through creating cloud-based software tools for digital DNA sequence editing, designing and running experiments, analyzing data, and sharing research. Benchling software includes an electronic lab notebook that allows researchers to document their experiments. It was founded in 2012 and is headquartered in San Francisco, California, United States.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $50M raised in May, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  98. two women sitting beside table using MacBooks


  99. Pheronym (Less than $1M)

    Pheronym is creating an all-natural highly effective insect control for agriculture. By leveraging pheromone spray they double nematode’s effectiveness as an organic insecticide to rival chemicals, without any of the negative health or environmental impact.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  100. tennis table in room


  101. Vaxcyte ($1M to $10M)

    Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

    • $1M to $10M annual revenues
    • 11-50 employees
    • $110M raised in March, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  102. photo of industrial machines near table


  103. Nutcracker Therapeutics (Less than $1M)

    Nutcracker Therapeutics is a biotech company that develops and produces mRNA therapeutics on its proprietary, microfluidic, and biochip-based platform. The company specializes in a fully-integrated system for the production of mRNA-therapeutics at the push of a button that enables scalable on-demand experimental and manufacturing capacity, thereby enabling healthcare companies to produce complex multimodal therapeutics at point of care. Nutcracker Therapeutics combines the productivity of RNA biology with innovations inspired by semiconductor manufacturing techniques to develop a proprietary miniaturized platform that enables the rapid discovery, development, and manufacturing of mRNA therapies and vaccines. Its ACORN platform is a first-of-its-kind, computer-controlled RNA manufacturing system that starts with a nucleic acid sequence of interest and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated, single-use biochips. Igor Khandros and Benjamin Eldridge established the company in Emeryville, California in 2017.

    • Less than $1M annual revenues
    • 11-50 employees
    • $60M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  104. people standiunmg


  105. Immune-Onc Therapeutics ($1M to $10M)

    Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $2.1M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  106. people sitting beside rectangular brown table with laptops


  107. Aimmune Therapeutics ($10M to $50M)

    Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $200M raised in February, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  108. men using computers


  109. Altay Therapeutics (Less than $1M)

    Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for chronic inflammatory conditions. It is currently focused on finding curative therapies for fibrosis, NASH, and liver cancer. It develops novel small molecule drugs against transcriptional regulators that are validated drivers of disease. It was founded in 2019 and is headquartered in San Francisco, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in March, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  110. two men using computers


  111. Biomea Fusion ($10M to $50M)

    Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer patients. Biomea Fusion has a development portfolio that targets specific gene alterations which occur in the DNA of patients that translate into key drivers of tumor growth. It is Biomea’s goal to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful treatments for patients in need. The lead program targets the protein-to-protein interaction between menin and the MLL complex for the treatment of various tumors.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $56M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  112. architectural photo of buildings during daytime


  113. Sutro Biopharma ($10M to $50M)

    Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $144.9M raised in December, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  114. man in black jacket sitting on chair


  115. D2G Oncology (Less than $1M)

    D2G Oncology is a biotechnology company that specializes in developing drugs to genotypes to transform precision cancer therapeutics. The company was founded by Jonathan MacQuitty in 2018 and is headquartered in Mountain View, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $8.7M raised in February, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  116. people sitting and using laptops


  117. Cytek Biosciences ($1M to $10M)

    Cytek Biosciences provides solutions that enable scientists to rapidly, efficiently obtain deep biological insights through high quality, high parametric datasets. Cytek manufactures and supplies flow cytometry products and services. Cytek’s compact, affordable instruments, and wide-ranging support offerings are used by researchers and clinicians all over the world. Cytek is focused on accelerating the adoption of flow cytometry to fuel scientific discovery. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $120M raised in November, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  118. people sitting on black chairs


  119. Change Foods ($10M to $50M)

    CHANGE is a US-Australian startup producing animal products that we love the most - without the environmental, ethical and health issues associated with farming animals. We do this by using cutting edge biotechnology and precision fermentation to create bio-identical compounds, and then formulating these into animal-free products that are indistinguishable from the real thing. Today, we're changing dairy, and creating delicious cheese that melts and stretches. All without lactose, hormones and antibiotics - this is dairy, done different.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.2M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  120. people sitting on chairs near tables during daytime


  121. Datavant ($1M to $10M)

    Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and sharing health data. The platform that the company offers organizes healthcare data for use in clinical trial decision-making. Its focus is on the employment of artificial intelligence to improve the clinical trial process and to improve the design and interpretation of clinical trials, helping pharmaceutical companies to manage the privacy, security, compliance, and trust required to enable safe data sharing. Travis May established Datavant in San Francisco, California in 2017.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $40M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  122. rectangular brown wooden table


  123. CODA Biotherapeutics ($1M to $10M)

    CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.7M raised in November, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  124. Revolution Medicines ($10M to $50M)

    Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines. REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology. REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $260.9M raised in February, 2021
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  125. brown wooden table and chairs


  126. Menten AI (Less than $1M)

    Menten AI designs new protein drugs and enzymes using quantum computers and machine learning. Proteins are large molecules that can twist into many shapes. Discovering the right shape for a protein to be a drug or a biocatalyst among almost endless possibilities is a major challenge. Menten AI solves this problem by using machine learning and quantum computing to find better starting points for discovery and further development. Quantum computing makes it possible to represent multiple states of the protein simultaneously and efficiently find the best designs. The team created the world’s first peptide designed on a quantum computer and is now working on peptide therapeutics for oncology and neurodegeneration, as well as on enzymes for industrial applications.

    • Less than $1M annual revenues
    • 1-10 employees
    • $4M raised in June, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  127. selective focus photography of desk lamp on table


  128. Veracyte ($10M to $50M)

    Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $550M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  129. rolling armchair beside table


  130. PicnicHealth ($1M to $10M)

    PicnicHealth is all about making medical records easy to access and using data to power the next frontier of medical research. We’re led by the belief that there’s power in medical information when it’s used well, and that every person has a right to their own theirs. And we've built award-winning machine learning to do it. How? PicnicHealth works directly with patients to give them the only tool anywhere that truly provides all of their medical records from any doctor or healthcare system in the US—in an easy-to-use, secure online dashboard. Not only that, but patients can choose to contribute their data to scientific research, which helps life sciences researchers accelerate breakthroughs in care. Researchers use this anonymized “real-world data” to understand how diseases are experienced by patients and treated by clinicians in the real world, going beyond the highly controlled setting of clinical trials. The goal is to create better treatments that can ultimately improve outcomes for patients. Whether you’re a scientist, engineer, or patient yourself, we’re looking for passionate people to join us in redefining an industry during our next stage of growth. To date we’ve helped tens of thousands of patients, partnered with some of the world’s largest biopharma companies, and raised more than $35M from Felicis Ventures, Amplify Partners, Foresite Capital, Refactor Capital, and Y Combinator.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $25M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  131. three women sitting around table using laptops


  132. Virus Geeks Inc. (Less than $1M)

    Virus Geeks is a data-driven BioHealth technology company that develops health-centric initiatives to improve the quality of life through strategic partnerships across healthcare & biotechnology sectors. We help communities gain access to COVID-19 testing and related healthcare benefits.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.1M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  133. grayscale photo of people in room


  134. Corvus Pharmaceuticals ($1M to $10M)

    Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $30M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  135. men sitting of chair inside room


  136. Darmiyan ($10M to $50M)

    Darmiyan has developed a novel, proprietary, patent-protected technology called The Virtual Microscope (Software Algorithm). Using a non-invasive routine clinical brain MRI scan, The Virtual Microscope technology looks into the human brain and localizes and quantifies cell distortion (neurodegeneration) in every voxel of brain MRI generating new brain maps. The first clinical product of this technology is BrainSee, an AI-powered algorithm that has completed a successful third-party validation in the US and Canada establishing a remarkable accuracy and consistency for prognosis of mild cognitive impairment. It is built on over 40 years of cutting-edge neuroscience research combined with advanced medical image analysis and AI, and has received official approval from the late Prof. Paul Greengard, Nobel Laureate in Physiology/ Medicine 2000.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $6.4M raised in April, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  137. Spectrum Antimicrobials ($10M to $50M)

    Spectrum Antimicrobials is a pharmaceutical company that specializes in the fields of drug development, antibiotics, and therapeutics. The company has created two significant broad-spectrum (non-antibiotic based) chemistries to combat viral, bacterial, fungal and mold caused infection in wounds, surgical sites, eyes, body cavities, and in the lung without causing antibiotic resistance. It was founded in 2016 and headquartered in Petaluma, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $18.2M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  138. people sitting in front of computer monitors


  139. Zymergen ($100M to $500M)

    Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more. It was founded in 2013 and headquartered in Emeryville, California.

    • $100M to $500M annual revenues
    • 501-1000 employees
    • $300M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  140. man in gray sweatshirt sitting on chair in front of iMac


  141. Trace Genomics ($1M to $10M)

    Trace Genomics has developed the first analytics engine that learns as it maps the living soil. Founded in 2015 to serve the farming community, Trace Genomics helps agronomists and their growers maximize the value of every acre. It was founded in 2015 and headquartered in Burlingame, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $17.2M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  142. people using desktop computer inside office


  143. Pionyr Immunotherapeutics (Less than $1M)

    Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

    • Less than $1M annual revenues
    • 11-50 employees
    • $275M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  144. group of people sitting beside rectangular wooden table with laptops


  145. Assertio ($50M to $100M)

    Assertio is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain, and Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for Gralise, Cambia, Zipsor, and Lazanda.

    • $50M to $100M annual revenues
    • 501-1000 employees
    • $34.3M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  146. rectangular brown wooden table with chair lot inside building


  147. Rakuten Medical ($10M to $50M)

    Rakuten Medical is a privately funded clinical-stage biotechnology company with offices in the USA, Japan, and Germany. Rakuten Medical has been developing new anticancer therapies based on the Photoimmunotherapy platform. Rakuten Medical plans to become a fully integrated biopharma with research, development, and worldwide commercialization of therapies based on the Photoimmunotherapy platform. Rakuten Medical was established in 2010 and is based in San Mateo, California.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $0.8M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  148. grey wooden table and black leather rolling chairs


  149. SonALAsense ($10M to $50M)

    SonALAsense develops SDT (Sonodynamic Therapy) intended to turn glioblastoma multiforme (GBM) patients into cancer survivors. It utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells. Their use of an MRI-guided focused ultrasound device with ALA is a true drug-device combination, where both the drug and the device are required for a therapeutic effect. SDT has a well-elucidated mechanism of action (creation of reactive oxygen species). The company was founded in 2019 and is based in Berkeley, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $1M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  150. people having meeting on rectangular brown table


  151. Day One Biopharmaceuticals ($10M to $50M)

    Day One Biopharmaceuticals is a biotechnology company focused on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of people of all ages living with cancer starting from the biology of childhood cancer. Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies. Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $130M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  152. man and woman sitting at table


  153. Geltor ($1M to $10M)

    Geltor is the bio-design company creating high-value designer proteins, including collagen. Its proteins are 100% animal- and GMO-free, and are cultivated using a sustainable fermentation process. Geltor’s products provide unprecedented functionality and benefits for consumers, while producing less waste and consuming fewer natural resources than archaic protein production platforms such as animals.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $91.3M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  154. brown and white table and chairs


  155. Ashvattha Therapeutics (Less than $1M)

    Ashvattha Therapeutics creates products that selectively target and treat human diseases. Ashvattha enables precision targeting for therapeutics eliminating off-target toxicity, systemic side effects, and immunogenicity seen in other platforms. Ashvattha has a pipeline of nine therapeutics in neurology, oncology, and ophthalmology.

    • Less than $1M annual revenues
    • 11-50 employees
    • $12M raised in May, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  156. two women sitting beside table using MacBooks


  157. Perfuse Therapeutics ($10M to $50M)

    Perfuse Therapeutics specializes in developing therapies for the treatment of eye disease. The company is pursuing a novel mechanism to treat various eye diseases, starting with glaucoma, by improving retinal perfusion.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $9M raised in July, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  158. tennis table in room


  159. CareDx ($10M to $50M)

    CareDx is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products under development. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $164M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  160. photo of industrial machines near table


  161. Alladapt Immunotherapeutics ($1M to $10M)

    Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $60M raised in February, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  162. people standiunmg


  163. Lyell Immunopharma ($10M to $50M)

    Lyell Immunopharma is focused on advancing the science of T-cell differentiation, functionality, and specificity so that they can develop curative treatments for human diseases. Lyell Immunopharma is headquartered in South San Francisco, California.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $493M raised in March, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  164. people sitting beside rectangular brown table with laptops


  165. Tolerion ($1M to $10M)

    Tolerion is a biotechnology company addressing the cause of autoimmune diseases through bio-therapeutic. They use our novel antigen-specific immune tolerance induction platform to engineer product candidates that restore balance in autoimmune conditions in which self-antigens (or “autoantigens”) incite a destructive immune response. Tolerion was founded in 2001 and is headquartered in South San Francisco, California, USA.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $20M raised in January, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  166. men using computers


  167. SilviaTerra ($1M to $10M)

    SilviaTerra's vision is that our planet's forests would be fully understood and fairly valued. To that end, we believe that measurements make markets. So we use our high-resolution forest data to underpin markets in carbon offsets, biodiversity, fire risk reduction, and more.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $4.4M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  168. two men using computers


  169. Enable Medicine ($10M to $50M)

    Enable Medicine is a biotechnology company based in Menlo Park, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $3.6M raised in August, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  170. architectural photo of buildings during daytime


  171. Amunix ($1M to $10M)

    Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness the immune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies. Amunix was founded in 2006 and is headquartered in Mountain View, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $73M raised in March, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  172. man in black jacket sitting on chair


  173. LevitasBio ($1M to $10M)

    Levitas, Inc. is redefining cellular analytics with its novel platform magnetic levitation technology. Their disruptive technology overcomes the current technological limitation of cellular analysis by providing label-free, simple, and universal methods of analysis. The company's platform, the LeviCell enables studies and beneficial uses of previously inaccessible, high-value primary samples, and sensitive cell types regardless of the starting cell number, viability, or sensitivity to processing.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $18M raised in January, 2021
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  174. people sitting and using laptops


  175. Mantra Bio ($1M to $10M)

    Mantra Bio develops a novel next-generation, targeted therapeutics based on its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). The Company's REVEAL platform, which integrates computational and wet biology, and automation, leverages the diversity of exosomes to enable the rational design of therapeutics directed at a wide range of tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process and related technologies to ensure this new class of therapeutics is reproducibly made at high purity.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $25M raised in July, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  176. people sitting on black chairs


  177. Pacific Biosciences ($10M to $50M)

    Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. Pacific Biosciences offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. It also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Pacific Biosciences' customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. Joseph Bonventre and Stephen Turner founded Nanofluidics in 2000 that laterbecame Pacific Biosciences. Its headquarters is in Menlo Park in California.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $900M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  178. people sitting on chairs near tables during daytime


  179. Alamar Biosciences ($1M to $10M)

    Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $14M raised in May, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  180. rectangular brown wooden table


  181. ZBiotics (Less than $1M)

    ZBiotics is a synthetic biology company founded in 2016 and headquartered in San Francisco, California. The company bioengineers probiotic bacteria for nutraceutical and other applications. ZBiotics is pioneering the use of genetically engineered probiotics to solve intractable problems.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2.3M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  182. NuLeaf Tech Inc (Less than $1M)

    In wastewater, treatment plants are “on-grid”. Off-grid means unique on-site treatment for each business, residence, or community. Unfortunately, on-grid treatment plants are crumbling in the face of urbanization. For off-grid, septic tanks are common but are ineffective and can cost $100,000 to install! This is a multi-billion dollar problem across the US, but it is felt most severely in low-income communities. This problem will only get worse with climate change looming. Off-grid water solutions are necessary for a future where no one has to worry about dirty water. Enter the NuTree - a novel on-site wastewater treatment device. It empowers everyday people to treat their own water by harnessing nature’s methods. The NuTree is no harder to maintain than a fish tank or small garden, which makes the system easy to construct and affordable to maintain. Its modular units, at under $10,000 each, can scale to treat the waste from a single household to a growing business. With a circular, zero-waste system that includes water recycling, bioenergy, and growing crops the NuTree is a force of nature. Ket Metrics: --Backed by Sean O’Sullivan VC, Venture-Net Partners, and several private angels --Generated revenue from Mastercard, breweries, and several residents in the Bay Area --In negotiations for municipal pilot units in Madagascar, India, and Portland, OR --A total $270 billion market in the US. Our beachhead markets are in the Pacific Northwest, particularly tiny homes and rural communities. We’re raising a seed round at a discount to our Series A share price. These funds will be used to leverage our momentum in the Pacific Northwest into our Series A with Venture-Net and Sean O’Sullivan VC.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in February, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  183. brown wooden table and chairs


  184. OncoCyte (Less than $1M)

    OncoCyte is a biotechnology company that focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company's mission is to provide actionable answers to physicians and patients at critical decision points along the lung cancer care continuum, to optimize diagnosis and treatment, improve patient outcomes, and reduce the overall cost of care. OncoCyte was established in 2009 and is based in Alameda, California.

    • Less than $1M annual revenues
    • 51-100 employees
    • $5M raised in January, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  185. selective focus photography of desk lamp on table


  186. Genetic Foresight ($1M to $10M)

    Genetic Foresight’s mission is to prevent adverse drug reactions, increase therapeutic success rates, and minimize healthcare costs by enabling clinicians to make informed decisions. Founded in 2016, Genetic Foresight provides a genetic test that sequences targeted segments of patients' genomes as well as a comprehensive prescription decision platform that incorporates drug-genome, drug-drug, drug-disease, personal health, lifestyle, and medical and family histories to predict drug response. This allows the clinician to more safely and effectively prescribe medication based on the patient. The report is updated based on newly generated research, newly created drugs, and newly prescribed drugs, making it a lifetime test.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $17.6M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  187. rolling armchair beside table


  188. Air Protein ($10M to $50M)

    Air Protein is a startup that aims to develop sustainable protein made from thin air. Using a proprietary probiotic process, Air Protein develops protein-enriched food made from CO2. This revolutionary new protein source can be used to make meat-free burgers, protein-enriched pasta, cereals, beverages, and more. Air Protein has been developed by Kiverdi, a California-based biotechnology company.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $32M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  189. three women sitting around table using laptops


  190. Hospi (Less than $1M)

    Hospi Corporation improves the quality of life by innovating practical, high impact medical devices that enhance patient comfort and wellbeing, ease caregiver burden, and reduce cost. Its patient-centric focus is informed by a nursing perspective and has guided the development of Hospi’s first product, the Macy Catheter®, which has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is now available in the United States. The Macy Catheter was invented by Hospi co-founder Brad Macy, a 20-year hospice nurse veteran, who leveraged his experience to address the need for a product to help improve patient comfort and wellbeing. The Macy Catheter is a simple, patented, and innovative medical device designed to facilitate discreet and comfortable rectal administration of liquids or medications. The rectal route of administration is relevant, yet underutilized, in the hospice, palliative care, and home health settings. It is particularly useful for the management of symptoms when a patient has difficulty swallowing or the oral route is otherwise compromised.

    • Less than $1M annual revenues
    • 11-50 employees
    • $3.5M raised in May, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  191. grayscale photo of people in room


  192. ApexQubit ($1M to $10M)

    ApexQubit is a biotechnology company that is harnessing frontier technologies for discovery of new medicines and better health for humanity.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $0.1M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  193. men sitting of chair inside room


  194. Natera ($50M to $100M)

    Natera is driven by a passion for elevating the science and utility of prenatal testing. The advent of the Information Age has created a paradigm shift in the fields of computing and informatics. Surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing.

    • $50M to $100M annual revenues
    • 251-500 employees
    • $250M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  195. Genapsys ($1M to $10M)

    GenapSys is actively looking to partner with local health agencies and researchers to arm researchers with access to the insight afforded by sequencing. With its sequencing technology, the company aims to help support the control and limit the spread of current and future outbreaks. The device can run off of a standard power source and is small enough to fit in the back of a truck or be deployed at hospitals, airports, and public transportation hubs for quick results on virus samples. It was founded in 2010 and headquartered in Redwood City, California.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $75M raised in February, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  196. people sitting in front of computer monitors


  197. Ivy Natal ($10M to $50M)

    Ivy Natal develops a process to create human egg cells from skin samples as a treatment for most cases of infertility.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.3M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  198. man in gray sweatshirt sitting on chair in front of iMac


  199. Frontier Bio (Less than $1M)

    Frontier Bio has developed a bioprinter that combines conventional bioprinting techniques with electro-hydrodynamic printing (EHDP). Their patent-pending technology is the only method which can print at the micro and nanoscale while maintaining high cell viability.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.8M raised in February, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  200. people using desktop computer inside office


  201. Nurix Therapeutics ($10M to $50M)

    Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases. The company’s product engine leverages a deep mechanistic understanding of the UPS to deliver effective small molecule drug candidates with the potential to make a dramatic difference for patients. Nurix drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. The company discovers drugs that harness the body's natural process to control protein levels. Their focus is on developing drugs to treat cancer including the novel, small molecule immuno-oncology agents. Nurix was founded in 2009 by internationally recognized experts in the ubiquitin-proteasome field and is funded by leading life science investors, Third Rock Ventures, and The Column Group. The company is headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $120M raised in March, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  202. group of people sitting beside rectangular wooden table with laptops


  203. Ace Vision Group ($10M to $50M)

    Ace Vision Group is a medical device company developing eye laser technology and natural therapeutic procedures to treat age-related eye dysfunction. Ace Vision is the developer of the VisioLite® bladeless microsurgery Er:YAG Ophthalmic Laser System and patented innovative LaserACE® procedure for the treatment of presbyopia (the progressive loss of the eye’s ability to focus on close objects that typically becomes apparent in a person’s early to mid-40’s).

    • $10M to $50M annual revenues
    • 51-100 employees
    • $13.3M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  204. rectangular brown wooden table with chair lot inside building


  205. LeafWorks ($1M to $10M)

    LeafWorks is an alternative biotech company, specializing in plant identification, research and development for the cannabis, hemp and herbal industries.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1M raised in February, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  206. grey wooden table and black leather rolling chairs


  207. Koya Medical ($10M to $50M)

    Koya Medical mission to treat cancer-related chronic lymphedema and venous diseases through innovative patient-centric platforms.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $11M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  208. people having meeting on rectangular brown table


  209. BillionToOne ($1M to $10M)

    BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting with developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $15M raised in March, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  210. man and woman sitting at table


  211. Nautilus Biotechnology ($10M to $50M)

    Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $76M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  212. brown and white table and chairs


  213. InterVenn (Less than $1M)

    InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides. It was founded in 2017 and headquartered in Redwood City, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $34M raised in November, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  214. two women sitting beside table using MacBooks


  215. Kenzen (Less than $1M)

    Kenzen creates personal health wearables to support its users in all dimensions of health, including wellness, activities, 3D motion, and performance. The company provides its clients with a variety of personal health monitors that report data in real time to smartphone devices. Through its data, Kenzen aims to enable individuals to make critical decisions in training and competitions. Its primary product, Kenzen ECHO, is a small, flexible patch that helps its users understand their physiology, and get personalized health insights and notifications to help improve performance, recovery, and prevent injury. Kenzen was founded in 2014 by Sonia Sousa and Steve Pecko. It is based in San Francisco, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  216. tennis table in room


  217. Bolt Biotherapeutics (Less than $1M)

    Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy. Its platform, Boltbody, is a cancer immunotherapy that consists of immune-stimulating antibody conjugates.

    • Less than $1M annual revenues
    • 11-50 employees
    • $93.5M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  218. photo of industrial machines near table


  219. Facile Therapeutics ($10M to $50M)

    Facile Therapeutics is a biotechnology company that develops therapeutic drugs for clostridium difficile infection. The company demonstrated Ebselen, an anti-toxin that doesn't cause the death of healthy gut bacteria that makes the colon resistant to C diff reinfection. Facile Therapeutics was founded in 2017 by Marc Navre and Matthew Bogyo and is based in Belmont, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $18.3M raised in February, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  220. people standiunmg


  221. Nesos ($10M to $50M)

    Nēsos develops and commercializes electrical field treatments for neurological disorders. It is critically supported by expert clinical and scientific collaborators from leading academic institutions, including Stanford, Vall d'Hebron, Harvard, Mount Sinai, Feinstein Institute, University Of California, San Diego (UCSD), and the University Of California, San Francisco (UCSF). It was co-founded by Konstantinos Alataris and other neuroscientists.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $16.5M raised in December, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  222. people sitting beside rectangular brown table with laptops


  223. Brex ($10M to $50M)

    Brex is reimagining financial systems so every growing company can realize their full potential. With the financial OS, new customers can get up and running in minutes with corporate credit cards and cash management in a single, strategic account. Plus, companies save hours every month with built-in tools and integrations to track spend, and earn points on every card purchase. Launched in 2018, Brex has raised $315M in equity funding alongside $350M in debt financing, and is backed by the likes of Y Combinator Continuity, Kleiner Perkins, and the founders of PayPal. Headquartered in San Francisco, Brex also has offices in Vancouver, B.C. and the Salt Lake valley. Brex was founded by Henrique Dubugras and Pedro Franceschi, two engineers who previously founded Pagar.me, one of the largest payment processors in Brazil with over $1.5 billion in GMV.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $150M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  224. men using computers


  225. Protera ($1M to $10M)

    Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed. Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $5.6M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  226. two men using computers


  227. Retrotope (Less than $1M)

    Retrotope creates a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases. It is a privately held company focused on the development of ways of controlling metabolic processes associated with oxidative stress conditions. Retrotope uses isotope effect to slow down damaging pathways. The company has several discovery and development programs that involve major classes of biopolymers, with the major focus on neurological diseases such as Friedreich's ataxia. It was founded in 2006 and is located in Los Altos Hills, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $50M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  228. architectural photo of buildings during daytime


  229. Corinth MedTech ($1M to $10M)

    Corinth MedTech, a small startup company located in Cupertino, CA, and founded in 2014, developed a bipolar transurethral and transcervical resection system intended for endoscopically controlled tissue removal for male patients diagnosed with benign prostatic hyperplasia (BPH), and female patients diagnosed with Abnormal Uterine Bleeding (AUB), fibroids and/or polyps requiring Hysteroscopic tissue removal.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $5M raised in December, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  230. man in black jacket sitting on chair


  231. Eureka Therapeutics ($10M to $50M)

    Eureka Therapeutics is a biotechnology company that focuses on immunotherapies for the treatment of cancer. The company's platform is a novel T-cell therapy construct that mimics the natural biology of T-cells to fight cancer. It utilizes a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. Eureka Therapeutics was founded in 2006 and is headquartered in Emeryville, California.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $45M raised in March, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  232. people sitting and using laptops


  233. EnGen Bio ($10M to $50M)

    EnGen Bio is a development-stage biotechnology company that pioneers a new approach to preventing and treating influenza. It believes that it has identified a candidate Universal Type A Influenza vaccine. Influenza drugs and vaccines are unique because there is sufficient government funding available to develop these assets well into human clinical trials, and possibly to market. EnGen Bio is aggressively pursuing this and similar opportunities. It is founded in 2017 and is headquartered in Redwood City, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.6M raised in January, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  234. people sitting on black chairs


  235. Felix Biotechnology (Less than $1M)

    Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases. Felix Biotechnology's bio-therapeutics targets antibiotic-resistant bacteria to manage infectious diseases precisely and effectively, allowing healthcare professionals to manage urgent microbial challenges in human health.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  236. people sitting on chairs near tables during daytime


  237. Tulavi Therapeutics ($1M to $10M)

    Tulavi Therapeutics is a biotechnology company that is dedicated to developing new therapies to treat neurally mediated disease. The company's solution is dedicated to developing therapies that directly target the nerves to prevent and/or treat aberrant neural reflex arcs in the peripheral and visceral disease that can be administered through surgical and interventional approaches, enabling physicians to treat such diseases in a better way. It was founded in 2018 and is headquartered in Mountain View, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $3M raised in May, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  238. rectangular brown wooden table


  239. Freenome ($10M to $50M)

    Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention. Charles Roberts, Gabriel Otte, Riley Ennis, and Michael Otte launched the company in 2014 in South San Francisco, California.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $270M raised in August, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  240. Arcus Biosciences ($1M to $10M)

    Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer. It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio. Arcus was formed in 2015 in Hayward, California by Terry Rosen and Juan Jaen.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $220.4M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  241. brown wooden table and chairs


  242. Dropprint Genomics ($10M to $50M)

    Dropprint Genomics provides cell technology and machine learning models that characterize the immune system. It offers big data to the immune system by generating personalized maps of a patient's immune systems to better understand, control, and improve immune health. Jimmie Ye, Meena Subramaniam, and Rachel Gate co-founded San Francisco, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.2M raised in March, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  243. selective focus photography of desk lamp on table


  244. Rigel Pharmaceuticals ($10M to $50M)

    Rigel Pharmaceuticals, Inc. (Rigel), is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $16.5M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  245. rolling armchair beside table


  246. Rubedo Life Sciences ($10M to $50M)

    Rubedo Life Sciences is a biotechnology company based in Sunnyvale, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $12M raised in December, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  247. three women sitting around table using laptops


  248. 23andMe ($100M to $500M)

    23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

    • $100M to $500M annual revenues
    • 501-1000 employees
    • $82.5M raised in December, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  249. grayscale photo of people in room


  250. Apollomics ($1M to $10M)

    Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $124.2M raised in November, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  251. men sitting of chair inside room


  252. PMV Pharmaceuticals ($10M to $50M)

    PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $70M raised in August, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  253. New Age Meats (Less than $1M)

    New Age Meats is a biotechnology company that develops healthy cultivated meat grown from animal cells instead of animal slaughter.

    • Less than $1M annual revenues
    • 11-50 employees
    • $2M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  254. people sitting in front of computer monitors


  255. Coral Genomics (Less than $1M)

    Coral Genomics generates novel data sets to fill gaps in large-scale biobanks with clinical diagnostics that facilitate medication selection for diverse populations. Integrating molecular, functional, and clinical factors to optimize treatment for chronic disease, Coral works with healthcare systems to provide end-to-end precision medicine support from next-generation sequencing through patient/provider facing healthcare reports that create more personalized and efficient healthcare delivery.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2M raised in October, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  256. man in gray sweatshirt sitting on chair in front of iMac


  257. Inflammatix ($1M to $10M)

    Inflammatix develops a novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. The company was founded by Timothy Sweeney and Jonathan Romanowsky in California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $1.1M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  258. people using desktop computer inside office


  259. Dren Bio ($10M to $50M)

    Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $60M raised in October, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  260. group of people sitting beside rectangular wooden table with laptops


  261. Sagimet Biosciences ($1M to $10M)

    Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASN inhibitors.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $80M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  262. rectangular brown wooden table with chair lot inside building


  263. Apexigen ($1M to $10M)

    Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company’s proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease mechanisms. Apexigen pioneers a movement into therapeutics based on rabbit-derived humanized monoclonal antibodies as a means of providing therapeutic benefits that have not been achieved through the use of other technologies. Several blockbuster antibody drugs have been developed with existing mouse and human antibody technologies and display libraries. However, the development of the next generation of antibody-based drugs will require capabilities that exceed those of current technologies in order to bind rare or intractable antigen epitopes and to exert novel effects on disease processes. The key to these next generation therapeutics lies in harnessing the inherent advantages of rabbit antibodies, which have been used successfully in research settings for decades. These advantages are the result of rabbit’s ability to generate a much greater diversity of unique high quality antibodies - with high affinity, high specificity and which bind unique antigen epitopes. These attributes enable the discovery of antibodies that are capable of targeting previously unreachable disease mechanisms.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $65M raised in March, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  264. grey wooden table and black leather rolling chairs


  265. Pivot Bio ($1M to $10M)

    Pivot Bio is improving and using a deep understanding of the microbiome to advance crop nutrition. They believe that microbes can deliver nutrients, protect against pests, and improve crop quality better than chemical fertilizers and pesticides. They leverage engineering principles and data science to map the dynamics of the plant microbiome and evolve beneficial traits. Their team thrives on collaboration and communication as they seek to create revolutionary fertilizers that transform food supply and improves the planet. Pivot Bio's proprietary ON Technology harnesses the power of naturally occurring microbes to provide more nutrients to crops. It’s a smart, sustainable way for farmers to improve yield as they work to help feed the world’s growing population. Their current efforts are focused on enabling microbes to fix and supply more nitrogen to corn. Pivot Bio was founded in 2010 and is headquartered in Berkeley, California, United States.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $100M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  266. people having meeting on rectangular brown table


  267. rBIO (Less than $1M)

    Pharmaceutical Manufacturing Using Synthetic Biology

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in February, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  268. man and woman sitting at table


  269. Oyster Point Pharmaceuticals ($100M to $500M)

    Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).

    • $100M to $500M annual revenues
    • 11-50 employees
    • $120.8M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  270. brown and white table and chairs


  271. Revelation Biosciences ($10M to $50M)

    Revelation Biosciences develops immunologic therapeutics and diagnostics designed to make the world a healthier place.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $4.4M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  272. two women sitting beside table using MacBooks


  273. protocols.io ($1M to $10M)

    Bring structure to your research. protocols.io is a secure platform for developing and sharing reproducible methods. Our platform enables scientists to make, exchange, improve, and discuss protocols. We aim to accelerate research by increasing collaboration and sharing among researchers, while improving efficiency.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $3.7M raised in January, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  274. tennis table in room


  275. Carmot Therapeutics (Less than $1M)

    Carmot Therapeutics, Inc. provides drugs to treat inflammatory, metabolic, and neurological diseases. The company was founded in 2008 and is based in San Francisco, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $47M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  276. photo of industrial machines near table


  277. Celevity ($1M to $10M)

    Celevity is a seed-stage company that develops drugs to help dogs live longer, healthier lives. It sees aging as a disease that is able to be slowed and improved with medicines. It was spun out of Laura Deming’s The Longevity Fund. Celevity is headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $4.9M raised in January, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  278. people standiunmg


  279. SOMOS (Less than $1M)

    Somos is a Mexican company of genetic solutions that offers you evidence of global ancestry and Latin American ancestry with an important differentiator: ancestry of Latin American groups, which makes it the first test to offer this kind of information.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  280. people sitting beside rectangular brown table with laptops


  281. Tallac Therapeutics ($10M to $50M)

    Tallac Therapeutics offers next-generation immunotherapies for cancer patients. The company is based in Burlingame, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $62M raised in December, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  282. men using computers


  283. Pliant Therapeutics ($10M to $50M)

    Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $100.4M raised in March, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  284. two men using computers


  285. CytoVale (Less than $1M)

    Categorized is a medical technology company that revolutionizes diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California, United States.

    • Less than $1M annual revenues
    • 11-50 employees
    • $8M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  286. architectural photo of buildings during daytime


  287. Seer (Less than $1M)

    Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.

    • Less than $1M annual revenues
    • 51-100 employees
    • $55M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  288. man in black jacket sitting on chair


  289. Ionpath ($1M to $10M)

    Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $18M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  290. people sitting and using laptops


  291. BigHat Biosciences (Less than $1M)

    BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.

    • Less than $1M annual revenues
    • 11-50 employees
    • $19M raised in February, 2021
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  292. people sitting on black chairs


  293. AmbAgon Therapeutics ($10M to $50M)

    AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $7.2M raised in July, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  294. people sitting on chairs near tables during daytime


  295. VastBiome ($1M to $10M)

    VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $4.5M raised in November, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  296. rectangular brown wooden table


  297. Soley Therapeutics (Less than $1M)

    Soley Therapeutics combines AI with molecular and cellular response detection for developing new efficacious drugs, using image acquisition-based approaches. Soley Therapeutics has taken an orthogonal approach to discover new drugs by developing a technology platform to measure how cells respond multi-dimensionally in response to drugs. We have developed a novel platform for high-content phenotypic drug screening, where the drug effect on a cell can be visualized via molecular-microscopic images and analyzed by using sophisticated AI tools.

    • Less than $1M annual revenues
    • 1-10 employees
    • $20M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  298. Titan Pharmaceuticals (Less than $1M)

    Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders. Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations. The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties. Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes. Finally, Titan is also entitled to royalty revenue of 8-10% of net sales of Fanapt® (iloperidone), an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG (“Novartis”) under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension). Substantially all of this future royalty revenue has been sold to Deerfield Management (“Deerfield”), a healthcare investment fund, in exchange for cash and debt considerations which have been used to advance the development of Probuphine and for general corporate purposes.

    • Less than $1M annual revenues
    • 11-50 employees
    • $9.7M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  299. brown wooden table and chairs


  300. Genesis Therapeutics ($1M to $10M)

    Their academia-leading research was the initial component of our expanding portfolio of AI technologies. They are combining novel deep neural networks, biophysical simulation, and massively scalable computing infrastructure to achieve industry-leading performance in a molecular generation and property prediction. The company was founded in 2019 and based in South San Francisco, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $52M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  301. selective focus photography of desk lamp on table


  302. Biotricity (Less than $1M)

    Biotricity is a medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual.

    • Less than $1M annual revenues
    • 11-50 employees
    • $9.5M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  303. rolling armchair beside table


  304. Durect Corp. ($10M to $50M)

    DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs

    • $10M to $50M annual revenues
    • 51-100 employees
    • $42.5M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  305. three women sitting around table using laptops


  306. BioXplor (Less than $1M)

    BioXplor is an augmented intelligence platform for data-driven hypotheses generation & novel predictions in biomarker & drug discovery. The virtual discovery platform is built on the intersection of big data, artificial intelligence and high performance computing, and works by enabling accelerated data interpretations from unstructured literature & structured multi-omics data. In house & external projects are focused on AI-assisted biomarker discovery, molecular target identification and drug repurposing, presently in cancer and rare disease.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in June, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  307. grayscale photo of people in room


  308. Vivace Therapeutics ($1M to $10M)

    Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway. At Vivace Therapeutics, they pursue their work with passion, driven by a conviction to help people fight cancer and live life to the fullest. Based in the San Francisco Bay Area, Vivace Therapeutics is an oncology-focused portfolio-based drug discovery and development company adopting a capital-efficient and modality-indifferent approach to bring novel therapies to patients in need. Their experienced management team and world-class scientists work to advance promising drugs and therapeutic technologies that they believe can help conquer cancer.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $30M raised in December, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  309. men sitting of chair inside room


  310. ANA Therapeutics (Less than $1M)

    ANA Therapeutics is a developer of a novel coronavirus vaccine intended to save human lives. It is developing therapeutics to solve the coronavirus pandemic using Niclosamide that enables medical practitioners to treat patients suffering from COVID-19. It was founded in 2020 and is headquartered in Foster City, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in August, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  311. DiCE Molecules (Less than $1M)

    ​Founded in 2013, DiCE Molecules develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its core technology was invented by Stanford Professor Pehr Harbury, a 2005 recipient of the Macarthur "genius" award. In addition to Professor Harbury, the founding team includes Dr. Phil Patten, formerly of Maxygen, Achaogen, and DuPont, who serves as our Chief Scientific Officer; Dr. John Bedbrook, a renowned serial entrepreneur in the agricultural biotechnology space, who is the Chairman of the DiCE Board of Directors; and Dr. Kevin Judice, who served various leadership roles at Genentech, Theravance, and Achaogen prior to joining DiCE as CEO.​​​

    • Less than $1M annual revenues
    • 11-50 employees
    • $80M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  312. people sitting in front of computer monitors


  313. IgGenix (Less than $1M)

    IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

    • Less than $1M annual revenues
    • 1-10 employees
    • $10M raised in August, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  314. man in gray sweatshirt sitting on chair in front of iMac


  315. Q Bio ($1M to $10M)

    Q Bio provides the first clinically relevant whole body analytics platform. In 60 minutes they analyze medical history, genetics, biochemistry, vitals, and perform a whole body MRI. The platform identifies changes over time associated with the earliest stages of disease before symptoms arise. The company was founded in 2015 and is headquartered in Redwood City, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $40M raised in February, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  316. people using desktop computer inside office


  317. Encoded Therapeutics (Less than $1M)

    Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovascular disease, enabling medical practitioners to treat patients and improve their lives.

    • Less than $1M annual revenues
    • 11-50 employees
    • $135M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  318. group of people sitting beside rectangular wooden table with laptops


  319. Catalyst Biosciences (Less than $1M)

    Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $50M raised in January, 2021
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  320. rectangular brown wooden table with chair lot inside building


  321. Amyris ($10M to $50M)

    Amyris Biotechnologies creates renewable products that focus on fuels and chemicals that provide no-compromise sustainable alternatives to a broad range of petroleum-sourced products. It uses an industrial synthetic biology platform that applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. Its technology creates products that support biopharmaceutical drug discovery and production, from cosmetic emollients and fragrances to fuels, solvents, lubricants, and nutraceuticals. The company was founded in 2003 and is headquartered in Emeryville, California.

    • $10M to $50M annual revenues
    • 501-1000 employees
    • $200M raised in June, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  322. grey wooden table and black leather rolling chairs


  323. Imago BioSciences ($10M to $50M)

    Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians. The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases. Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $80M raised in November, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  324. people having meeting on rectangular brown table


  325. IDbyDNA ($1M to $10M)

    IDbyDNA develops the technologies that will enable nucleic acid based identification of any life form on Earth. IDbyDNA is on a mission to empower clinicians and researchers to identify any pathogen from any sample.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $20M raised in January, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  326. man and woman sitting at table


  327. Cellares ($10M to $50M)

    Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit. The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope. Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources, and is difficult to scale. Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively and at the scale they need. The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $18M raised in October, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  328. brown and white table and chairs


  329. Kyverna Therapeutics (Less than $1M)

    KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.

    • Less than $1M annual revenues
    • 11-50 employees
    • $25M raised in January, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  330. two women sitting beside table using MacBooks


  331. Fountain Therapeutics ($1M to $10M)

    Fountain Therapeutics is discovering and developing treatments for aging-associated diseases. Fountain Therapeutics was founded with the belief that a future in which we live healthier lives longer is more desirable than one in which the company continues to be afflicted by the disease of aging. The company builds a transformative model of aging that re-creates many of the complex hallmark features of aging but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $6M raised in February, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  332. tennis table in room


  333. Deepcell (Less than $1M)

    Deepcell is an artificial intelligence company based in Mountain View, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $20M raised in December, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  334. photo of industrial machines near table


  335. Surrozen ($1M to $10M)

    Surrozen is a biopharmaceutical company that focuses on developing regenerative medicines that unlock the self-renewal properties of the body through specific control of the Wnt signaling pathway. It was founded in 2016 and is headquartered in South San Francisco, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $50M raised in June, 2020
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  336. people standiunmg


  337. MicroByre (Less than $1M)

    MicroByre is a biotechnology company that specializes in microbiology, synthetic biology, molecular biology, and computational biology. It domesticates and then genetically engineers otherwise reluctant, recalcitrant, and rebellious bacteria. It was founded in 2017 and headquartered in California, United States.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2.2M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  338. people sitting beside rectangular brown table with laptops


  339. Equator Therapeutics ($1M to $10M)

    Equator Therapeutics develops a drug that burns calories and improves metabolism. It offers a drug that can solve obesity and type 2 diabetes problem because it addresses the root cause of metabolic disorders. Its drug will target mitochondria, the powerhouse of the cell. It will activate the protein that mitochondria naturally use to produce heat. The company's approach has been proven to reverse obesity and type 2 diabetes in animals. It has developed a high-throughput drug discovery platform to identify compounds that selectively activate its target protein, without side effects.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.2M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  340. men using computers


  341. Amfora ($10M to $50M)

    Amfora is an emerging leader in the use of biotechnology to address the rapidly growing global demand for protein. Amfora is working to develop nutritionally enhanced forage crops for a market expected to have an annual value of as much as $12 billion a year. The company is based in San Francisco, California and is a portfolio company of Spruce Capital Partners LLC/MLS II Fund.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $7.3M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  342. two men using computers


  343. Vera Therapeutics ($1M to $10M)

    Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential. The company's gene-editing technology can potentially cure patients with sickle cell disease, cystic fibrosis, and other devastating genetic disorders, enabling physicians to improve gene detection and regulation.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $80M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  344. architectural photo of buildings during daytime


  345. PETcoil (Less than $1M)

    Founded in 2018, we are a group of imaging scientists, engineers, and radiologists aspired to improve healthcare by creating novel medical imaging technology and bringing it to every patient that needs it. Our core technology has its roots at Stanford University, where our founders created the first-ever radiofrequency-penetrable PET insert system for simultaneous PET and MRI imaging.  ​Our vision is to make multi-modality medical imaging accessible to every patient. Our mission is to create affordable, high-performance molecular imaging systems that empower doctors to drive early and accurate diagnosis of diseases.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1M raised in April, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  346. man in black jacket sitting on chair


  347. Tiamat Sciences (Less than $1M)

    Tiamat is a start-up producing affordable animal-free growth factors and biomolecules using plants as bioreactors. Thanks to its propriety platform, the company can manufacture a wide range of high-value proteins from antigens to growth factors. The company has already achieved a 10x cost reduction and at scale can get costs down 1000x even at 80% growth-margins, giving them a wide ability to price strategically. the coming years. The low investment needed to build a facility (up to 40x less than current solutions) combined with its unique technology makes Tiamat the ideal partner in production scale-up for promising markets that will soon become enormous such as cellular agriculture or cell & gene therapy.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.4M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  348. people sitting and using laptops


  349. Terns Pharmaceuticals ($10M to $50M)

    Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets. Based in San Mateo, California and Shanghai, Terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in China and globally.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $87M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  350. people sitting on black chairs


  351. Mekonos Inc. ($1M to $10M)

    Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $4.6M raised in November, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  352. people sitting on chairs near tables during daytime


  353. Swiftscale Biologics (Less than $1M)

    Swiftscale Biologics is a healthcare service provider that develops life-saving drugs. Its drugs are designed to improve the lives of the patients. The company was founded in 2019 and is headquartered in South San Francisco, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $11M raised in June, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  354. rectangular brown wooden table


  355. Kodiak Sciences ($1M to $10M)

    Kodiak Sciences is designing and developing novel therapies for the treatment of retinal disease. As a rapidly growing biopharmaceutical company, we are working every day to build value for the benefit of our community of patients, physicians, employees, families, and vendors. We want to have real impact, and we take a long term view. We are committed to ethics and excellence in everything we do. We are looking to hire top talent comfortable with ownership and accountability of exciting programs while collaborating effectively with colleagues inside and outside the company.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $560.9M raised in November, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  356. Annexon Biosciences ($1M to $10M)

    Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $100M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  357. brown wooden table and chairs


  358. Onc.AI (Less than $1M)

    Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics. The company develops a comprehensive approach to oncology diagnostics and uses deep learning to derive actionable insights into oncology treatment. It was founded in 2020 by Akshay Nanduri and Salmaan Ahmed and is based in San Carlos, California, United States.

    • Less than $1M annual revenues
    • 1-10 employees
    • $6M raised in December, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  359. selective focus photography of desk lamp on table


  360. Karius ($10M to $50M)

    Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $165M raised in February, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  361. rolling armchair beside table


  362. MicuRx Pharmaceuticals ($10M to $50M)

    MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $7.8M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  363. three women sitting around table using laptops


  364. Qualio ($10M to $50M)

    Qualio is a SaaS quality management platform that helps life sciences companies become quality-driven and accelerate growth. It unites their quality team, tools, and data - helping teams building life-saving products get to market quickly and scale successfully. It was founded in 2012 and is headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $11M raised in July, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  365. grayscale photo of people in room


  366. Rani Therapeutics ($1M to $10M)

    Rani Therapeutics develops an oral biotherapeutics technology for the oral delivery of large drug molecules, including peptides, proteins, and antibodies. The company was founded in 2012 and is based in San Jose, California.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $69M raised in December, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  367. men sitting of chair inside room


  368. Aerin Medical ($1M to $10M)

    Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing. Its device utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion, enabling patients suffering from nasal breathing disorders to open their nasal airway quickly, safely, and effectively.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $48M raised in August, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  369. Cyagen Biosciences ($1M to $10M)

    Founded in 2006, Cyagen Biosciences Inc. is a 300-employee contract research organization and cell culture product manufacturer with offices in Silicon Valley, California and in China. As a leader in custom animal models and molecular biology tools, Cyagen prides itself on the mission of bringing outstanding-quality research reagents, tools, and services to the worldwide biological research community at highly competitive prices.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $41M raised in February, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  370. people sitting in front of computer monitors


  371. 89bio ($1M to $10M)

    89bio is a clinical-stage biopharmaceutical company focused on rapidly advancing our lead product candidate, BIO89-100, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH). BIO89-100 is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It may be a differentiated FGF21 therapy, and we believe it has the potential to become a mainstay of therapy for NASH given its ability to address the key liver pathologies (steatosis and fibrosis) and underlying metabolic dysregulation in patients with NASH. We are also expanding the breadth of indications for BIO89-100 with an initial focus on severe hypertriglyceridemia (SHTG).

    • $1M to $10M annual revenues
    • 11-50 employees
    • $83.8M raised in July, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  372. man in gray sweatshirt sitting on chair in front of iMac


  373. Artemys Foods ($10M to $50M)

    Artemys Foods works on the next generation of meat alternatives by cultivating meat, instead of harvesting meat from animals. Artemys develops and executes a strategic vision for a biomanufacturing company that grows meat from animal cells, thereby empowering humanity to eat sustainable food.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  374. people using desktop computer inside office


  375. ProLynx ($10M to $50M)

    ProLynx develops advanced linker technologies and a facile with a transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates. The company's technology is dedicated to the development of linker systems to enable predictable and controllable half-extension of drugs. ProLynx was founded in 2009 by Daniel V. Santi and Gary W. Ashley and is based in San Francisco, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  376. group of people sitting beside rectangular wooden table with laptops


  377. Pylum Biosciences ($10M to $50M)

    Pylum Biosicences offers an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. The Avidocin platform can be quickly modified to generate new protein complexes to kill emerging strains as their genome sequences become available. Avidocin proteins employ a unique killing mechanism that is oblivious to the mechanisms bacteria have evolved to resist traditional antibiotics, and because of their tailorable specificity, they can be directed against specific species or strains with minimal or no off-target effects. The company currently has in development Avidocin agents targeting 10 different organisms including threatening human pathogens such as C. difficile, uropathogenic E. coli, and K. pneumonia. Pre-clinical animal studies have demonstrated that Avidocin proteins can be orally or parentally administered to prevent or treat disease with impressive efficacy in multiple infection models.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $1M raised in February, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  378. rectangular brown wooden table with chair lot inside building


  379. Actym ($1M to $10M)

    Actym is a biotechnology company that focuses on developing an immuno-oncology platform. It specializes in the fields of medical device, manufacturing, and distribution. It focuses on a novel tumor-targeting, systemically-delivered STING pathway agonist that demonstrates robust anti-tumor. It was founded in 2017 and headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $34M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  380. grey wooden table and black leather rolling chairs


  381. Spruce Biosciences ($1M to $10M)

    Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $88M raised in February, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  382. people having meeting on rectangular brown table


  383. Cellworks (Less than $1M)

    Cellworks Group operates as a life sciences technology company. The company provides iC-PHYS, a technology platform that enables drug and biomarker discovery and research in focused therapeutic areas. The company provides disease-focused drug discovery and research solutions in the areas of oncology, such as integrated tumor cell and endothelial cells with stromal inputs; inflammation diseases, such as macrophage, neutrophil, osteoclast, and T-cell; type-2 diabetes; infectious diseases; skin pigmentation and aging; and neurodegenerative. The company was founded in 2005 and is based in Saratoga, California. It has a research and development facility in Bangalore, India.

    • Less than $1M annual revenues
    • 51-100 employees
    • $15.5M raised in June, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  384. man and woman sitting at table


  385. Circle Pharma ($1M to $10M)

    Circle Pharma is an early stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diverse macrocycle scaffolds selected for inherent permeability. The company was founded by Prof. Matt Jacobson, Ph.D. (U.C. San Francisco) and Prof. Scott Lokey, Ph.D. (U.C. Santa Cruz) and is headed by David J. Earp, J.D., Ph.D.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $45M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  386. brown and white table and chairs


  387. Attralus ($10M to $50M)

    Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $25M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  388. two women sitting beside table using MacBooks


  389. AHEAD Medicine (Less than $1M)

    AHEAD Medicine focuses on developing AI-enabled immunoprofiling diagnostic for cancer precision medicine. Our lead product is AHEAD-flow platform, a machine learning based, fully automated analysis tool for clinical cytometry exams on blood cancer patients that is 100 times faster than current method. Here is the demo of our prototype: https://youtu.be/qcom2_RBDsA We have published our works in multiple international congresses and peer-reviewed journals. Our full list of publication could be found here: https://aheadmedicine.com/publications We also have co-development projects with pharmaceutical companies for immuno-oncology companion/complementary diagnostics in the pipeline. Currently, we are raising an equity round to establish a quality management system, complete FDA pre-submission meeting and kick off external validation study for our leading product AHEAD-flow platform.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.4M raised in January, 2020
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  390. tennis table in room


  391. Sound Agriculture ($10M to $50M)

    Sound Agriculture uses molecular discovery to create climate-resilient crops, enhancing harvest yields for growers. They also use an innovative life science approach to sustainably increase farming productivity. The company was founded in 2013 and headquartered in Emeryville, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $22M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  392. photo of industrial machines near table


  393. Spotlight Therapeutics (Less than $1M)

    Spotlight Therapeutics is a developer of gene editing therapeutics intended to edit specific cell populations directly in the body. The company's therapeutics are used to create next-generation programmable nucleases that can selectively target and edit cells, enabling physicians to treat their patient in an enhanced way.

    • Less than $1M annual revenues
    • 1-10 employees
    • $30M raised in November, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  394. people standiunmg


  395. Color ($50M to $100M)

    Color is a population health technology company that focuses on providing large-scale health care programs and clinical testing. It improves the key health infrastructure systems to make health accessible, convenient, and cost-effective, serving health systems, employers, research institutions, and individual consumers. Its Population Genomics Platform offers modular and end-to-end solutions that enable organizations to effectively build and scale population health programs. It provides technology, software, and clinical services to help population programs launch and scale quickly. By combining innovative technology, specialized laboratory infrastructure, and clinical health services, Color creates complete and effective programs that include: Program strategy, planning, and implementation; Participant outreach and engagement; participant education and consent about testing and results; sample (blood or saliva) collection and genetic sequencing; data management and clinical reporting; HIPAA compliance and data security; return of results; clinical services, like genetic counseling and clinical pharmacy; personalized care routine; and ongoing population health management. Color’s partners include NorthShore University Health System, the National Institutes of Health (NIH), Ochsner Health System, Verily, Visa, Levi Strauss, and Salesforce. Elad Gil, Nish Bhat, Taylor Sittler, and Othman Laraki launched Color in 2015 and is based in Burlingame, California.

    • $50M to $100M annual revenues
    • 251-500 employees
    • $167M raised in January, 2021
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  396. people sitting beside rectangular brown table with laptops


  397. Invenio Imaging ($1M to $10M)

    INVENIO IMAGING, Inc. is a privately held corporation founded in 2012 based on the research of Prof. Sunney Xie of the Department of Chemistry and Chemical Biology at Harvard University. Invenio is dedicated to developing a fast, reliable, simple-to-use technology for non-destructive microscopic analysis of the molecular make-up of tissues and other materials. INVENIO’s platform technology is positioned to enter the R&D microscopy market, and it is developing instrumentation for several high-value medical applications. INVENIO IMAGING Inc. acknowledges funding from the NSF and NIH SBIR programs.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $3M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  398. men using computers


  399. Boost Biomes ($1M to $10M)

    Boost Biomes develops microbial products to sustainably improve food production and shelf-life. It is a discovery platform that uses high throughput sequencing, selective enrichment, and advanced informatics to identify microbial products with important commercial roles. This approach is faster and less expensive than traditional approaches and uniquely identifies multi-microbial products which are often more effective than single microbe products. Boost Biomes was founded in 2016 and is headquartered in South San Francisco, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $2M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  400. two men using computers


  401. Kriya Therapeutics ($1M to $10M)

    Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $80.5M raised in May, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  402. architectural photo of buildings during daytime


  403. Personalis ($10M to $50M)

    Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer-reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both invariant detection and interpretation.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $150.1M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  404. man in black jacket sitting on chair


  405. ImmunoMind ($10M to $50M)

    ImmunoMind is an AI-powered platform for drug discovery with single-cell precision. ImmunoMind enables fast discovery of biomarkers that increase the success rate of drug development programmes. The platform automates the biomarker discovery from single-cell immunogenomics data and can free up 85% of medical researchers’ time and speed up computations by 750%. ImmunoMind’s solutions are trusted by researchers and medical scientists from Pfizer, Novartis, Regeneron, UCSF, MIT, Stanford, John Hopkins School of Medicine and Vanderbilt Diabetes Center, with more than 30,000 users worldwide. ImmunoMind is UC Berkeley SkyDeck company.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in March, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  406. people sitting and using laptops


  407. Helix ($10M to $50M)

    Helix is the leading population genomics company working at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+™ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $33M raised in July, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  408. people sitting on black chairs


  409. Tizona Therapeutics ($1M to $10M)

    The company is establishing collaborations with its scientific founders “to better understand whether regulatory T cells play a more prominent role in certain tumors,” he added. Although research suggests that Tregs cells play a more prominent role in creating immunosuppression in the microenvironment in some tumor types than others, “quite honestly, the data are lacking. One of the ways we’re going to differentiate the company is to understand that relationship better.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $300M raised in July, 2020
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  410. people sitting on chairs near tables during daytime


  411. Base5 Genomics ($10M to $50M)

    Base5 Genomics is a developer of sequencing solutions used for personalized care. Its solution reveals the full genomic diversity in humans and other organisms that enable the medical community to give patients the personalized treatment they need. The company was founded in 2018 and is headquartered in Mountain View, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $1M raised in May, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  412. rectangular brown wooden table


  413. DNAnexus ($10M to $50M)

    DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomic medicine. DNAnexus provides security, scalability and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. It was founded in 2009 and is based in Mountain View, California.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $100M raised in June, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  414. PostEra ($1M to $10M)

    PostEra uses machine learning to close the design-make-test loop of drug discovery and reduce our clients' cycle times. We are currently leading an international team of scientists to find a COVID antiviral via on open science initative. Consider contributing your expertise to the initiative here: https://postera.ai/covid

    • $1M to $10M annual revenues
    • 1-10 employees
    • $2.3M raised in March, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  415. brown wooden table and chairs


  416. Codiak Biosciences ($10M to $50M)

    Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $57.8M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  417. selective focus photography of desk lamp on table


  418. Hexagon Bio ($10M to $50M)

    Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $47M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  419. rolling armchair beside table


  420. Orbus Therapeutics (Less than $1M)

    They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $10M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  421. three women sitting around table using laptops


  422. Checkerspot (Less than $1M)

    Checkerspot is a materials innovation company. Advances in our understanding of biology, chemistry and materials science are converging with breakthroughs in data science and unleashing capabilities they once only imagined. Checkerspot's technology unlocks this potential, expands the palette of materials available to product designers and enables a more intentional way to design performance materials for specific applications. As a graduate of the Illumina Accelerator program, we are building a technology platform that enables the design – at a molecular level – of new materials. Through applications development, they prototype and iterate on specific product embodiments. By engaging directly with product users and partnering with socially responsible corporations, they design and bring to market superior products with better materials.

    • Less than $1M annual revenues
    • 11-50 employees
    • $36M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  423. grayscale photo of people in room


  424. BrightInsight ($1M to $10M)

    BrightInsight provides a digital health platform for bio-pharma and med-tech. Its IoT platform is built under a quality management system to support and optimize regulated drugs, devices, and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. BrightInsight was founded in 2017 and is headquartered in San Jose, California.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $40M raised in June, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  425. men sitting of chair inside room


  426. Culture Biosciences ($1M to $10M)

    Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditional approaches by robotic sample handling and cloud data monitoring and analysis. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $15M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  427. InCarda Therapeutics ($1M to $10M)

    InCarda Therapeutics is a clinical-stage drug delivery company pioneering a novel approach of treating acute cardiovascular diseases/conditions by the inhalation route. Lead product is InRhythm, an inhaled formulation of an antiarrhythmic drug to treat acute paroxysmal atrial fibrillation events within minutes at home, at work, or anywhere. Completed Phase 1 and currently advancing lead product through Phase 2. InCarda Therapeutics was founded in Newark, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $30M raised in October, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  428. people sitting in front of computer monitors


  429. Enveda Biosciences ($10M to $50M)

    Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologies systematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration. Enveda, launched in 2019, is based in San Francisco, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $4.9M raised in August, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  430. man in gray sweatshirt sitting on chair in front of iMac


  431. Rain Therapeutics ($1M to $10M)

    Rain Therapeutics develops targeted therapies for patients with cancer. We begin by identifing cancers with a single, and clear, oncogenic driver and evaluating sub-populations of cancer populations with an unmet need, where standards of care are ineffective. Our global scientific and thought-leader network drives our asset and technology identification to match these cancers with small molecule therapeutics targeted at treating specific cancer mutations.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $63M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  432. people using desktop computer inside office


  433. Grail ($50M to $100M)

    Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.

    • $50M to $100M annual revenues
    • 251-500 employees
    • $390M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  434. group of people sitting beside rectangular wooden table with laptops


  435. Unlearn.AI ($1M to $10M)

    Unlearn is the only company using AI to create Digital Twins to populate Intelligent Control Arms in clinical studies. By leveraging historical datasets and disease-specific machine-learning models, Unlearn generates virtual placebo patients, created from actual patient baseline data in clinical studies. This novel approach increases trial power and confidence, accelerates trial timelines, and enables patient level insights. Unlearn was founded in 2017 by a team of world-class machine learning scientists who shared a vision of using machine learning to streamline clinical trials. Unlearn has received a total of $20M in funding, most recently in a Series A extension lead by Eisai, Epic Ventures, and Alumni Ventures. Unlearn has authored a peer-reviewed publication in Nature, and is partnering with one of the world’s leading pharma companies. Digital Twins are currently part of an ongoing pivotal Alzheimer’s Disease trial. In 2020, Unlearn was named a CB Insights Digital Health 150 Company, and the winner of the Innovation Showcase at CNS Summit. Unlearn continues to have discussions with regulators, industry leaders, and other key stakeholders, and is seeking partners to help drive innovation in clinical research using AI.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $3M raised in November, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  436. rectangular brown wooden table with chair lot inside building


  437. Ansa Biotechnologies ($10M to $50M)

    Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerate innovation in biological research and engineering.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $7.9M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  438. grey wooden table and black leather rolling chairs


  439. Uniphore ($1M to $10M)

    Uniphore is a global Conversational AI technology company that offers a customer service platform that is powered by AI and automation technologies. The Company’s vision is to bridge the gap between people and machines through voice. Uniphore enables businesses globally to deliver transformational customer service by providing a platform of Conversational Analytics, Conversational Assistant and Conversational Security that changes the way enterprises engage their consumers, build loyalty and realize efficiencies. Uniphore was founded in 2008 and has offices in the U.S., India, and Singapore.

    • $1M to $10M annual revenues
    • 251-500 employees
    • $14.1M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  440. people having meeting on rectangular brown table


  441. 4D Molecular Therapeutics ($10M to $50M)

    4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $75M raised in June, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  442. man and woman sitting at table


  443. Katana Pharmaceuticals ($10M to $50M)

    Katana Pharmaceuticals is a biotech company developing novel treatments for neonatal patient populations and rare pediatric disorders.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $1.1M raised in June, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  444. brown and white table and chairs


  445. Ceribell ($10M to $50M)

    Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective. The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision making. The Ceribell EEG System can be set up by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $20M raised in May, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  446. two women sitting beside table using MacBooks


  447. Correlia Biosystems ($1M to $10M)

    Correlia Biosystems, Inc. is a spinout from UC Berkeley developing protein measurement tools that are cost-efficient, rapid, and customizable. Their versatile SimpleScan technology has applications ranging from point-of-care diagnostics to rapid and multiplexed proteomics research.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $9.6M raised in October, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  448. tennis table in room


  449. BIOAGE LABS (Less than $1M)

    BIOAGE discovers and develops drugs to treat aging and associated diseases.

    • Less than $1M annual revenues
    • 11-50 employees
    • $90M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  450. photo of industrial machines near table


  451. Coherus Biosciences ($100M to $500M)

    Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates.

    • $100M to $500M annual revenues
    • 251-500 employees
    • $50M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  452. people standiunmg


  453. Syapse ($1M to $10M)

    Syapse works with leading health systems, life sciences companies, and regulators to accelerate real-world evidence to improve the outcomes of cancer patients. By bringing these organizations together into the Syapse Learning Health Network, Syapse has built one of the world’s largest networks dedicated to improving outcomes in cancer care through improved precision medicine. Syapse and its partners are working towards a future in which all cancer patients have access to the quality of care they need. The company was founded in 2008 and is headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $30M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  454. people sitting beside rectangular brown table with laptops